Program
evolocumab
Also written as “Evolocumab”, “Evolocumab AI/pen” and “Evolocumab Drug Substance A (Test)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia, led by 4 companies.
Drug pageEvolocumab: every studyAll 108 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 422 open or running | phase 4since Jan 3, 2018 | May 27, 2010 | May 29, 2027phase 4 · NCT05284747 |
| ECRI bvits history only | 10 open or running | phase 4since Feb 12, 2019 | Feb 12, 2019 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 4since Oct 10, 2022 | Oct 10, 2022 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Nov 7, 2017 | Nov 7, 2017 | none ahead |
Also a collaborator on its studies: GE Healthcare and HeartFlow.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 7, 2017First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03337698 · 314 enrolled · United States, Australia, France and more
TargetBeta
“A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SYH2053rule | CSPC Pharmaceutical Group | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
The one study Hoffmann-La Roche leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Oct 14, 2025 | 314 |
How it is read
Names in the registry
- “Evolocumab”, 39 entries
- “evolocumab”, 2 entries
- “Evolocumab AI/pen”, 2 entries
- “Evolocumab Drug Substance A (Test)”, 1 entry
- “Evolocumab Drug Substance B (Reference)”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 15 studies
- Hyperlipidemias, 12 studies
- Dyslipidemias, 4 studies
- Coronary Artery Disease, 3 studies
- Homozygous Familial Hypercholesterolemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.